Lilly to present new cancer drug data at ASCO 2017

Lilly will be presenting new clinical data on a range of cancer therapies at this year's annual meeting of the American Society of Clinical Oncology (ASCO).

Running from June 2nd to 6th in Chicago, the conference will see the company discuss new study findings with a focus on targeting the biology of cancer to find new ways to fight the disease and improve care.

Highlights include an oral presentation of data from the phase III trial MONARCH, showing the effectiveness of the investigational cyclin-dependent kinase 4 and 6 inhibitor abemaciclib in the treatment of breast cancer.

Additionally, new data from the company's ongoing immuno-oncology clinical collaborations with Merck Sharp and Dohme will be shared, with the results of two trials evaluating pemetrexed plus carboplatin and ramucirumab in combination with Merck's pembrolizumab.

Dr Levi Garraway, senior vice-president for global development and medical affairs at Lilly Oncology, said: "We are pleased to share how we are building foundational therapeutics with the goal of delivering medicines that help people with cancer live longer and healthier lives."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.